This Global website is not intended to represent or suggest that particular products are approved or authorized in any particular jurisdiction. You should not construe anything on this website as a promotion or solicitation for any product or service, or as suggesting that a product or service be used where it is not approved or authorized by applicable law and regulation in a particular country, territory, or jurisdiction. To learn which products are approved or authorized in particular countries, please consult the appropriate country-specific website.
This content is intended for use by healthcare professionals.

1. Fitzmaurice DA, Blann AD, Gregory YH. ABC of antithrombotic therapy. Bleeding risks of antithrombotic therapy. BMJ 2002;325(7368):828–31.
2. Hoffbrand AV, Moss PAH, Pettit JE. Coagulation disorders. Essential Haematology. 5th ed: Blackwell Publishing, 2009:290–302.
3. Wiedermann CJ, Stockner I. Warfarin-induced bleeding complications - clinical presentation and therapeutic options. Thromb Res 2008;122 Suppl 2:S13-8.
4. Vigue B, Ract C, Tremey B, Engrand N, Leblanc PE, Decaux A, et al. Ultra-rapid management of oral anticoagulant therapy-related surgical intracranial hemorrhage. Intensive Care Med 2007;33(4):721-5.
5. Esmerio FG, Souza EN, Leiria TL, Lunelli R, Moraes MA. Constant Use of Oral Anticoagulants: Implications in the Control of Their Adequate Levels. Arq Bras Cardiol 2009;93(5):508–12.
6. Koo S, Kucher N, Nguyen PL, Fanikos J, Marks PW, Goldhaber SZ. The effect of excessive anticoagulation on mortality and morbidity in hospitalized patients with anticoagulant-related major hemorrhage. Arch Intern Med 2004;164(14):1557-60.
7. Makris M, Watson HG. The management of coumarin-induced over-anticoagulation Annotation. Br J Haematol 2001;114(2):271-80.
8. Hanley JP. Warfarin reversal. J Clin Pathol 2004;57(11):1132-9.
9. Hoffbrand AV, Moss PAH, Pettit JE. Thrombosis and antithrombotic therapy. Essential Haematology. 5th ed: Blackwell Publishing, 2009:303–19.

LinkedIn Twitter Facebook Google+